Skip to main content

Table 1 Differences in survival between patients assigned to each dacetuzumab sensitivity class according to each classifier.

From: Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data

Classifier

Selected Genes

Sens/Semi/Resis Log-rank p-values

Sens/Resis Log-rank p-values

SNSS/SNSS

2 genes total: RGS13, HSP90B1

0.0013

7 × 10-4

Lasso/RF

10 genes total: RGS13, CRTC3, PRPSAP2, PVRIG, SORD, WIPF1, CSNK2A2, GNB5, ERAP1, CAMSAP1

0.0125

0.0212

Lasso/KNN

1 gene total: RGS13

0.0304

0.0077

RDA/RF

11 genes total: GRK5, GNB5, IFITM1 (2 probe sets selected), CSNK2A2, SCARB1, UGDH, MSH2, GORASP1, PECI, VPS54, WWOX

0.0573

0.34

SNSS/KNN

2 genes total: RGS13, HSP90B1

0.0706

0.4661

SNSS/RF

12 genes total: RGS13, HSP90B1, PRPSAP2, IFITM1, SORD, PYROXD1, EVI2B, ZNF322A, NAGK, BTG2, RAB13, DPYD

0.1513

0.0556

RDA/KNN

2 genes total: GRK5, IFITM1 (2 probe sets selected)

0.4373

0.3035

Lasso/Lasso

No genes selected

-

-

RDA/RDA

No genes selected

-

-

  1. The genes selected by each classifier are summarized alongside p-values for the log-rank tests for differences between the survival rates of dacetuzumab sensitive, semi-sensitive, and resistant patients, and for the two-way difference between the survival rates of dacetuzumab sensitive and resistant patients only.